by Don McLean | Feb 7, 2020 | Blog
The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead by Aaron Robert The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers...
by Don McLean | May 9, 2019 | Blog
FREE DOWNLOAD: Lay Summary Whitepaper This complimentary lay summary whitepaper will explain: the ins and outs of lay summary writing, the importance of starting a pilot program, a checklist for lay reviewers, and strategic advice for becoming more transparent....
by Don McLean | Mar 14, 2019 | Blog
PhUSE: Retrospective vs. Proactive Anonymization of Narratives Exerpt from whitepaper originally published by PhUSE on March 14, 2019 by project co-leads – Rashmi Dodia, MS, RAC and Gregory Campbell, BS Executive Summary Ever since policy 0070 was first introduced in...
by Don McLean | Nov 8, 2018 | Blog
Why Lay Summaries Matter and Their Future by Staff writer Plain language summaries, commonly known as lay summaries, have become increasingly important for pharmaceutical companies in recent years. However, there are many sponsors that have yet to start their pilot...
by Don McLean | Sep 6, 2018 | Blog
Navigating the four types of clinical study reports by Staff writer Clinical Study Reports (CSRs) are critical documents that describe the methodology and results of a clinical trial in drug development. As of late, CSRs have been reviewed under a higher level of...
